Close

Achillion Pharma (ACHN) Announces Presentation of Odalasvir, AL-335 and Simeprevir Phase 2b Data

August 11, 2016 6:15 AM EDT Send to a Friend
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced that interim results from an ongoing phase 2a clinical trial, being conducted by Alios ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login